Presentation Features Analyses Based News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Presentation Features Analyses Based. Real-time updates on events, politics, business and more.

Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting

June 6, 2022

Poster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202) in Solid

United States Farletuzumab Ecteribulin Morab Ishin Nishio Eisai Co Ltd Department Of Obstetrics American Society Of Clinical Oncology

Source: finanznachrichten.de

Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting

June 5, 2022

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United States New Zealand Farletuzumab Ecteribulin Morab Michele Randazzo Prnewswire Eisai Ishin Nishio

Source: apnews.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Presentation Features Analyses Based News Today

Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting

Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting

Explore More Categories